Abstract

This contract has and will continue to play a crucial role in our vaccine development program. It provides a unique national and international resource which serves to move new vaccines and antimicrobials from the laboratory into man. In addition, by proving Koch's postulates for several suspect pathogens, the contract has opened the way for basic and applied scientific inquiry into several infectious diseases of man.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI062528-003
Application #
3595262
Study Section
Project Start
1985-11-30
Project End
1990-11-29
Budget Start
1986-11-14
Budget End
1987-11-29
Support Year
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201

  Publications

Sztein, M B; Tanner, M K; Polotsky, Y et al. (1995) Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J Immunol 155:3987-93
Wasserman, S S; Losonsky, G A; Noriega, F et al. (1994) Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12:1000-3
Wasserman, S S; Kotloff, K L; Losonsky, G A et al. (1993) Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect. Am J Epidemiol 138:988-93
Murphy, J R (1993) Diarrhoeal disease: current concepts and future challenges. Rapid detection of enteric infections by measurement of enteric pathogen-specific antibody secreting cells in peripheral blood. Trans R Soc Trop Med Hyg 87 Suppl 3:27-30
Hone, D M; Tacket, C O; Harris, A M et al. (1992) Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest 90:412-20
Suharyono; Simanjuntak, C; Witham, N et al. (1992) Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340:689-94
Keay, S; Tacket, C O; Murphy, J R et al. (1992) Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1. AIDS Res Hum Retroviruses 8:1091-8
Herrington, D A; Losonsky, G A; Smith, G et al. (1992) Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Vaccine 10:841-6
Dolin, R; Graham, B S; Greenberg, S B et al. (1991) The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 114:119-27
Murphy, J R; Grez, L; Schlesinger, L et al. (1991) Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect Immun 59:4291-3

Showing the most recent 10 out of 25 publications